Cargando…
HDL as a drug and nucleic acid delivery vehicle
This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620406/ https://www.ncbi.nlm.nih.gov/pubmed/26578957 http://dx.doi.org/10.3389/fphar.2015.00247 |
_version_ | 1782397291313758208 |
---|---|
author | Lacko, Andras G. Sabnis, Nirupama A. Nagarajan, Bhavani McConathy, Walter J. |
author_facet | Lacko, Andras G. Sabnis, Nirupama A. Nagarajan, Bhavani McConathy, Walter J. |
author_sort | Lacko, Andras G. |
collection | PubMed |
description | This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics. |
format | Online Article Text |
id | pubmed-4620406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46204062015-11-17 HDL as a drug and nucleic acid delivery vehicle Lacko, Andras G. Sabnis, Nirupama A. Nagarajan, Bhavani McConathy, Walter J. Front Pharmacol Pharmacology This review is intended to evaluate the research findings and potential clinical applications of drug transport systems, developed based on the concepts of the structure/function and physiological role(s) of high density lipoprotein type nanoparticles. These macromolecules provide targeted transport of cholesteryl esters (a highly lipophilic payload) in their natural/physiological environment. The ability to accommodate highly water insoluble constituents in their core regions enables High density lipoproteins (HDL) type nanoparticles to effectively transport hydrophobic drugs subsequent to systemic administration. Even though the application of reconstituted HDL in the treatment of a number of diseases is reviewed, the primary focus is on the application of HDL type drug delivery agents in cancer chemotherapy. The use of both native and synthetic HDL as drug delivery agents is compared to evaluate their respective potentials for commercial and clinical development. The current status and future perspectives for HDL type nanoparticles are discussed, including current obstacles and future applications in therapeutics. Frontiers Media S.A. 2015-10-26 /pmc/articles/PMC4620406/ /pubmed/26578957 http://dx.doi.org/10.3389/fphar.2015.00247 Text en Copyright © 2015 Lacko, Sabnis, Nagarajan and McConathy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lacko, Andras G. Sabnis, Nirupama A. Nagarajan, Bhavani McConathy, Walter J. HDL as a drug and nucleic acid delivery vehicle |
title | HDL as a drug and nucleic acid delivery vehicle |
title_full | HDL as a drug and nucleic acid delivery vehicle |
title_fullStr | HDL as a drug and nucleic acid delivery vehicle |
title_full_unstemmed | HDL as a drug and nucleic acid delivery vehicle |
title_short | HDL as a drug and nucleic acid delivery vehicle |
title_sort | hdl as a drug and nucleic acid delivery vehicle |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620406/ https://www.ncbi.nlm.nih.gov/pubmed/26578957 http://dx.doi.org/10.3389/fphar.2015.00247 |
work_keys_str_mv | AT lackoandrasg hdlasadrugandnucleicaciddeliveryvehicle AT sabnisnirupamaa hdlasadrugandnucleicaciddeliveryvehicle AT nagarajanbhavani hdlasadrugandnucleicaciddeliveryvehicle AT mcconathywalterj hdlasadrugandnucleicaciddeliveryvehicle |